Drug Profile

Lamotrigine orally disintegrating tablet

Alternative Names: EUR-1048; Lamictal ODT; Lamotrigine ODT

Latest Information Update: 16 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GlaxoSmithKline
Developer Adare Pharmaceuticals; GSK
Class Antidepressants; Antiepileptic drugs; Chlorobenzenes; Mood stabilisers; Small molecules; Triazines
Mechanism of Action Sodium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Bipolar disorders; Epilepsy

Most Recent Events

14 Feb 2022 US FDA approves generic lamotrigine orally disintegrating tablets
16 Jul 2016 No recent reports of development identified for phase-I development in Epilepsy(In volunteers) in Hong Kong (PO, Fast dissolve)
02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com